0001021771-24-000044.txt : 20240215 0001021771-24-000044.hdr.sgml : 20240215 20240215161135 ACCESSION NUMBER: 0001021771-24-000044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALSTODT LANCE CENTRAL INDEX KEY: 0001756228 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37603 FILM NUMBER: 24643921 MAIL ADDRESS: STREET 1: BIORESTORATIVE THERAPIES, INC. STREET 2: 40 MARCUS DRIVE, SUITE 1 CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioRestorative Therapies, Inc. CENTRAL INDEX KEY: 0001505497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 301341024 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: (631) 760-8100 MAIL ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: Stem Cell Assurance, Inc. DATE OF NAME CHANGE: 20101110 4 1 form4.xml X0508 4 2024-02-13 0001505497 BioRestorative Therapies, Inc. BRTX 0001756228 ALSTODT LANCE BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE, SUITE 1 MELVILLE NY 11747 true true true President, CEO, COB false Common Stock 189505 D Stock Option 5.08 2031-03-18 Common Stock 293479 293479 D Stock Option 5.08 2031-11-04 Common Stock 42059 42059 D Stock Option 2.91 2033-02-17 Common Stock 106762 106762 D Stock Option 1.45 2024-02-13 4 A 0 438596 0 A 2034-02-13 Common Stock 438596 438596 D Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. The option is currently exercisable. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested. The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. /s/ Lance Alstodt 2024-02-13